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CHAPTER I 
IHTRODUCTION 
The presence of a certain microbial population adjacent to, and 
within, the gingival sulcus is now considered to be the primary etiologic 
factor in the pathogenesis of most forms of periodontal disease. 1' 2' 3 
The rationale for conventional therapy, (e.g. periodontal scaling and 
root planing and patient oral hygiene procedures), is based on studies 
of experimental gingivitis. 4' 5 When oral hygiene measures are stopped, 
there is a shift in the microbial content of plaque from predominantly 
Gram-positive and coccoid, to one that becomes increasingly filamentous 
with various Gram-negative species. 
Actinomyces species has been found both in conjunction with 
gingivitis6' 7 and advanced periodontal disease. 8 Potentially important 
pathogens have been identified by Socransky9 and include spirochetes 
and various Gram-negative bacteria, such as Fusobacterium nucleatum, 
capnophilic fusiform rods known as "Capnocytophaga", corroding species 
of Vibrio, Bacteroides and Eikenella, Bacteroides melaninogenicus ss. 
asaccharolyticus as well as many unidentified Gram-negative organisms. 
Traditionally, the periodic removal of microbial plaque from 
the tooth surfaces has been a benchmark for the long term success of 
periodontal treatment,lO,ll, 12 ,13 It would appear that removing the 
microbes, or changing the microbial content to that associated with 
health, is indeed necessary. The amount of time and energy expended by 
the patient and clinician is extraordinary in accomplishing such a 
1 
result, and it is because of this that chemotherapeutic agents, 
especially the tetracyclines14 ,l 5,l 6,l 7,l 8 have come to the fore-
front of periodontal therapy. 
2 
CHAPTER II 
REVIEW OF THE LITERATURE 
A. The Microbiology of Periodontal Disease 
In 1958, Arnim recognized that the primary etiologic factor in 
periodontal disease was 11 the adherent colonized microbial mass found on 
the tooth surface at the gingival crest, in the sulcus and in the 
periodontal pocket with its associated bordering communications of motile 
and nonmotile bacteria, protozoa, leukocytes, drifting desquamated cells 
as well as other varieties of microscopic life, living or dead ... 21 More 
recently, there have been a number of longitudinal studies that have 
correlated the existence of bacterial plaque with the subsequent devel-
opment of gingival inflammation, In these studies, Loe, et a1. 22 , 23 
showed that a group of 12 dental students developed accumulations of 
soft debris (plaque) and clinically observable inflammation of the 
gingiva when oral hygiene measures were stopped. When oral hygiene 
measures were resumed, the plaque was removed and gingivitis abated. 
24 25 Lindhe and Nyman and Rosling et al. showed that the progress of 
advanced periodontal disease could be halted or partially reversed by 
surgical procedures when accompanied by twice monthly professional tooth 
cleaning. These studies suggest that suppression of the total microbiota 
could be effective in controlling both gingivitis and destructive perio-
dontitis in humans. The investigations described above deomstrated that 
a wide variety of microorganisms have been observed in plaque associated 
with periodontal disease states in man. However, until recently, only 
3 
4 
a few species have been shown to be capable of inducing similar disease 
in experimental animals or of satisfying Koch's postulates. 26 
Various studies have implicated certain species of the genus 
Actinomyces as major etiologic agents of gingivitis and periodontitis. 27 , 28 
These studies have also shown that periodontal disease is transmissible 
in rodent model systems. Hamsters monoinfected with A. viscosus develop 
signs of periodontal disease. Certain other species of the genus 
Actinomyces, such as A. naeslundii and A. israelii, which are found in 
plaque of patients with advanced periodontal disease, have been shown 
to cause destructive periodontal disease when transferred to gnotobiotic 
t 29,30 ra s. 
Specific.Gram-negative anaerobic or capnophilic organisms are 
capable of inducing severe periodontal breakdown with rapid alveolar 
. 31 32 bone loss in laboratory an1mals. ' It has also been shown that both 
juvenile and adult patients with aggressively osteolytic and with advanced 
periodontal disease have shown a predominance of Gram-negative anaerobic 
or capnophilic flora associated with the region of greatest pocket depth. 
33,34,35,36,37, 38 These organisms include Bacteroides corrodens, 
Eikenella corrodens, vibrio corroders and Campytobacter sp., fusiforms 
including Fusobacterium nucleatum and Fo polymorphum, Selenomonas 
sputigena and Bacteroides melaninogenicus. Spirochetes are also found 
to be abundant in the advanced periodontal lesion. Slots38 found that 
B. melaninogenicus ss. asaccharolyticus is the predominant Gram-negative 
rod isolated from deep pockets in adult advanced periodontitis. 
Newman, et al. 34 , 35 , 36 found a group of Gram-negative anaerobic 
capnophilic rods described as the "Periodontosis Group" and grouped I 
through V. Some of these have been named "Capnocytophaga" and 
Bacteroides ochraceus. 39 ,40 Unlike the adult form of periodontal 
5 
disease, the microflora of the juvenile form is saccharolytic. At least 
some of the microflora of the adult form of the aggressive disease are 
found in the juvenile disease and vice versa. In addition, these same 
microorganisms can be found in relatively normal sulci of patients with 
and without gingival disease, but in lower numbers. 41 Finally, Actino-
bacillus actinomycetecomitans (strain Y4), an anaerobic gram-negative 
microorganism, has been isolated from the subgingival plaque of patients 
"th . "1 • d t"t" 42 w1 JUVenl e per1o on 1 1s. Refer to Table 1-2 for the organisms 
found in health and periodontal disease. 
B. The Microflora•s Relationship to the Pathogenesis of Periodontal 
Disease 
An important feature in periodontal disease is the predominance 
of increasing numbers of white blood cells, specifically neutrophils, in 
the junctional epithelium and gingival sulcus as gingivitis is initiated 
and progresses to an established lesion. It has been demonstrated in 
vitro that dental plaque and sertain oral bacteria contain or produce 
neutrophil chemotactic factors. 43 ,44 ,45 Enzymes within the neutrophil 
1 bl f h d 1 . t . t. t . t 46 ysosomes are capa e o y ro yz1ng cer a1n 1ssue cons 1tuen s. 
The bacteria themselves have a direct effect on gingival 
inflammation by virtue of the production of enzymes or cytotoxic 
materials. Hyaluronidase is one such enzyme produced by oral bacteria, 
d "t t" "t h b detected ,·n dental plaque. 48 ,49 , 50 an 1 s ac 1v1 y as een It may be 
6 
a factor in the breakdown of intercellular substances and thus facilitate 
the penetration of other substances. 
Certain substances produced by the oral bacteria have toxic 
effects on cells, which could be a mechanism causing some cellular 
destruction. Their exotoxins may destroy erythrocytes (hemolysins), 
fibrin (fibrinolysins), and tissue (necrotoxins). Bacterial endotoxins 
(lipopolysaccharides) from the cell membrane (gram-negative organisms), 
may cause: a pyrogenic action resulting in an increase in the host's 
temperature; a transient leucopenia followed by leucocytosis; hypo-
glycemia; a wide variety of circulatory disturbances, especially 
hemorrhage; altered resistance to bacterial infection; and a vascular 
hyperactivity to ·adrenergic drugs. 51 
In various studies, stimulation of peripheral lymphocytes with 
antigen preparations from plaque or selected oral microroganisms induced 
a greater degree of blastogenesis in patients with some degree of perio-
dontal disease than in healthy individuals. 52 , 53 , 54 , 55 , 56 , 57 The pro-
duction of lymphokines, biologically active effector substances produced 
by sensitized lymphocytes, also has been reported when circulating 
lymphocytes are stimulated by antigens from plaque or oral microorganisms. 
56
,
58
,
59
,
60 These studies give evidence that the bacteria in plaque 
stimulate the host's cellular immunity, and therefore, are involved in 
the pathogenesis of periodontal disease. 
Various studies have shown serum antibody reaction with oral 
organisms, and thus there is stimulation of the host's humoral inmunity. 
Antibody has been detected to antigens from Fusobacterium, 61 ,62 
Actinomyces naeslundii 63 ,64 and Bacteroides melaninogenicus. 65 ,66 
Other organisms may also react with serum antibody. When bacterial 
7 
antigens to which there is an antibody titer enter the gingiva, antigen-
antibody complexes might form and cause extensive tissue damage. 
An overall view of the hypothesized role of bacteria in the 
pathogenesis of periodontal tissue destruction is seen below. 67 
Factors Active Against Intercellular Matrix~ 1 Enzymes? ~ 
Bacteria~Accumulation---Cytotoxic Agents----Tissue Destruction 
Metabolic End Products 
Cell Wall Constituents? 
Leukocyte Lysosjlmes? 
Direct Chemical Induction 
Hypersensitivity Immediate? 
Delayed? 
C. Tetracycline and Periodontal Disease 
It is a logical hypothesis that antibodies could effect a change 
in the composition of subgingival plaque if adequate levels are achieved 
in gingival fluid and saliva. Tetracycline, a broad-spectrum bacteria-
static agent used in the treatment of long-term bacterial diseases such 
as acne vulgaris, has been used for years as an adjunct in the treatment 
of periodontal disease. The basis for its selection has been its broad 
spectrum, low incidence of sensitivity in patients, and favorable safety 
record. 78 
8 
In addition, the tetracyclines have, in the past, been used for 
the following oral conditions: 
1. Recurrent aphthous stomatitis. 74 
2. Acute (primary) herpetic gingivostomatitis. 75 
3. To improve periodontal surgical results. 76 
4. As an initial therapy in acute necrotizing ulcerative 
. . •t• 77 g1ng1Vl lS. 
5. Periodontal abscess. 77 
Some have used tetracycline as an adjunct in the treatment of 
juvenile periodontitis and agressive forms of the disease in adults. 
Tetracycline has been used at high doses ( 1 gm/day) for short periods 
(10 to 30 days) a·nd at lower doses (250 mg to 500 mg/day) for extended 
periods in the management of periodontitis. 
Recent studies have evaluated the effectiveness of both short-
term and long-term use of tetracycline in the treatment of periodontal 
disease. In the studies by Hellden et a1. 79 and Listgarten, et a1. 80 
tetracycline administered orally for two weeks was compared with scaling 
and root planing in the treatment of advanced periodontal disease. Their 
results showed that the greatest reduction in pocket depth and clinical 
indexes of inflammation occured in the group that was treated by scaling 
and root planing. The addition of tetracycline to the group that 
received scaling did not improve the results. Tetracycline administered 
without conventional treatment gave results comparable with those from a 
control group who received only oral hygiene instruction. When sub-
gingival samples were examined the tetracycline alone group showed a 
9 
return of high numbers of spirochetes and gram-negative rods occuring 
between 8 and 25 weeks. In contrast, the microlfora of the scaled 
patients remained consistent with gingival health through the 25th week. 
In the Slots81 study, the clinical and microbiological effects 
of adjunctive tetracycline were not very different from the effects of 
periodontal scaling and root planing. However, in this study, two 
patients who did not respond well to scaling did show significant 
improvement in parameters examined after a two week course of the 
antibiotic. 
There have been very few studies on the effect of long-term 
tetracycline therapy in periodontal disease. The studies that have 
been done suggest that long-term therapy (250 mg/day) is not more 
advantageous than a two week course of 1000 mg/day. 82 ,83 
Lindhe, et a1. 84 found that tetracycline administered via a 
hollow fiber device markedly changed the composition of the subgingival 
flora of initially diseased periodontal sites. This method proved 
effective in reducing or eliminating the clinical symptoms of periodontal 
pathology. Goodson, et a1. 85 found that the hollow fiber filled with 
tetracycline virtually eliminated spirochetes after only a single 
application. Once eliminated, they do not recolonize even though there 
is a persistence of viable organisms elsewhere in the mouth. 
The side effects and toxicities of the tetracyclines are listed 
in Table 4. 
CHAPTER III 
MATERIALS AND METHODS 
A. Experimental Design 
Five patients, three females (PL,BR,SS) and two males (JC, JK) 
from Loyola University School of Dentistry, Department of Periodontics 
(Loyola University Medical Center Institutional Review Board #3/80-5a), 
were selected on the basis of the severity of their periodontitis. The 
age of the patients varied from 25 to 31 years with a mean of 27.2 years. 
In order to ascertain and determine the systemic health of the partici-
pants, a sequential multiple analysis (SMA-24) and a complete blood 
count was ordered from the clinical laboratory at Loyola University 
Medical Center. 
Each patient had at least one pair of contralateral teeth, with 
corresponding diseased surfaces, and where pockets could be probed to 
5mm or more. Radiographically, on the average, one half of the original 
alveolar bone had been lost. The participants had not received any 
antibiotics in the past 12 months, nor did they have any history of 
allergy, diabetes, blood dyscrasias, or chronic liver or kidney disease. 
None of the women were aware of being pregnant. 
Following the baseline examinations, the patients were randomly 
distributed into two groups, T1 and P1• The patients in group T1 
received 250 mg Achromycin v* (tetracycline hydrochloride), four times a 
*Lederle Laboratory 
10 
11 
day, for a 2 week period. The patients in group P1 received a placebo 
resembling the Achromycin capsule. Prior to the study, a code was 
assigned to both the Achromycin and the placebo capsules so that the 
examiner was unaware as to which patients were in which groupo There-
fore, the study was double-blind. 
All patients received a scaling on the contralateral tooth and 
received oral hygiene instructions after the second baseline examination. 
One week separated the first and second baseline examinations. Further 
examinations were conducted at the 3rd, 12th and 24th week of the study. 
This experimental design provided complete (i.e. 0-, 1-, 3-, 12- and 
24- week) data on diseases test sites which, had been left untreated 
(P1s0) scaled only (P1s1), tetracycline administration only (T1S0) and 
sites that received both scaling and tetracycline (T1S1). 
B. Parameters Tested 
The examination of sites listed in Table 5 involved as assessment 
of the following parameters: 
1. Gingival index (See Table 6) score was estimated on a scale 
of 0-3, according to the method of Loe and Silness. 19 Six areas were 
examined, i.e. on both the vestibular and oral surfaces, the mesial, 
distal and an area midway between these were examined. 
2. Plaque index (See Table 7) score was estimated on a scale 
of 0-3, according to the method of Silness and Loe. 20 
3. Probing depth was recorded with a color-coded periodontal 
probe* to the nearest mm. measurement. Measurements were made from 
both the vestibular and oral surfaces at the mesial, distal and a point 
12 
midway between these. 
4. Microbial content (percentage anaerobes, facultative and 
tetracycline resistnat organisms) at sites. (See Table 5) Prior to 
the sampling, supragingival deposits were removed from the isolated 
teeth with sterile gauze. Bacterial samples were obtained from sub-
gingival sites with a sterile paper point (Coarse)** placed as far 
subgingivally as possible into the periodontal pocket, until resistance 
was met. The paper point was left in place for 10 seconds, at the end 
of which time, it was immediately placed in 1 ml of sterile thioglycolate. 
This was repeated with another paper point. 
The subgingival deposits were displaced from the points and 
dispersed via vortex mixing for one minute. The bacterial suspension 
was serially diluted in 10-fold steps in dilution blanks with sterile 
saline. Three series of duplicate plates at the three dilutions were 
prepared for each sample. In addition to enriched blood agar, one of 
the series was supplemented with 1.0 ug/ml tetracycline hydrochloride. 
3 -4 -5 Aliquots of 0.1 ml from dilutions of 10- , 10 and 10 were placed on 
duplicate sets of growth media with sterile pipets. Plating was 
accomplished using a sterile bent rod. The plates were immediately 
placed in an anaerobic jar*** after which a vacuum was applied and an 
anaerobic grade gas was introduced. The vacuuming of the jar, followed 
by introduction of the anaerobic gas was done a minimum of three times 
(evacuation - replacement method). The anaerobic gas contained a mixture 
*Nordent Mfg. Corp. 
**Johnson & Johnson 
***BBL 
13 
of 5% carbon dioxide, 10% hydrogen and 85% nitrogen (Union Carbide, New 
York). The plates were incubated for at least 72 hours at 37°C. The 
presence of an anaerobic environment was monitored with oxygen-sensitive 
indicator strips (BBL). The third group of plates was incubated under 
aerobic conditions at least 72 hours at 37° C. After 72 hour growth 
period, viable counts were recorded from plates containing between 30 
and 300 colonies. These colonies were counted using a counting chamber 
with transmitted light and a magnifying lens. 
The growth media used for isolation of bacterial colonies was 
prepared by combining 3% Todd Hewitt Broth (BBL), 0.5% Yeast extract 
(BBL), and 1.5% granulated agar (BBL). After autoclaving, the growth 
media was allowed to cool to 60°C in a water bath after which time 5% 
defibrinated sheep•s blood*, 5.0 ug/ml hemin** and 0.5 ug/ml of 
menadione** was added. 
*Ovine Laboratories, Chicago 
**Syma Chemical Co., Mo. 
CHAPTER IV 
RESULTS 
Table 5 shows the distribution of patients used in this study 
and the treatment regimen received. The mean pocket depths ranged from 
5 mm to 9 mm. The gingival index ranged from 1.30 to 2.66 and the plaque 
index ranged from 0 to 2. Therefore, according to Table 8, all the test 
subjects had at least moderate inflammation or plaque accumulation. 
Table 5 shows three sites received placebo plus scaling, three sites 
received placebo only, two sites received tetracycline plus scaling and 
two sites received tetracycline only. 
A. Clinical Parameters 
The effect of the various treatment modalities on the gingival 
index is shown in Table 9. All patients with the exception of BR showed 
a reduction in the gingival index from the pretreatment period to Week 3 
(two weeks post treatment). In the placebo group, the mean gingival 
index reduction was greater at the site that was scaled, from Day 0 to 
Week 3. In the tetracycline group, the mean gingival index reduction 
was also greater in the sites that received tetracycline in addition to 
scaling. From Week 3 to Week 12, there continued a reduction in the 
gingival index scores. A significant reduction is seen with patient PL 
receiving placebo plus scaling and patient SS receiving the same regimen. 
However, patient JK receiving placebo only, had a significant reduction 
from 2.66 to 0.50. Patient JC showed a greater reduction in the. gingival 
index after tetracycline therapy, than after tetracycline plus scaling. 
14 
15 
Patient BR showed an equal reduction regardless of the treatment 
rendered. When the mean scores for all patients are compared, there is 
a greater reduction in the gingival index of the sites treated with 
placebo alone compared to treatment with palcebo plus scaling from 
Week 3 to Week 12. There is also a greater reduction in the gingival 
index from Week 3 ro Week 12 in the sites receiving tetracycline alone 
when compared to the sites receiving both tetracycline and scaling. 
The mean gingival index scores increased from Week 12 to Week 24, for 
all sites except for the sites receiving tetracycline plus scaling. 
These sites showed a continued reduction. No return to the pretreatment 
gingival index scores was noted in any case. 
Table 10 shows the changes in the plaque index scores over a 
24 week period. All sites showed a reduction in that score from Day 0 
to Week 3, with the exception of patient BR who was relatively constant 
throughout the 24 week period. When the mean scores are compared for 
all sites, the placebo group showed a similar reduction regardless if 
the site had been scaled or not and the tetracycline group showed a 
similar reduction from Day 0 to Week 3 regardless if the site had been 
scaled or not. From Week 3 to Week 12, there continued to be a reduction 
in the plaque index score; however, there was an increase in the plaque 
index score from Week 12 to Week 24 for most of the patients although 
it was still less than the pretreatment level. 
Table 11 shows the changes in the pocket depths over a 24 week 
period. The sites receiving placebo plus scaling showed a sustained 
reduction over the 24 week period. The sites receiving placebo alone 
16 
either remained relatively the same or increased in depth. The sites 
receiving tetracycline plus scaling and those receiving tetracycline 
alone showed a sustained reduction in pocket depth throughout the 24 
week period. 
B. Microbiological Parameters 
Table 12 shows the baseline values for the anaerobic, facultative 
and tetracycline resistant organisms. All patients and all sites showed 
a predominance of anaerobic organisms, when compared to a healthy 
individual (Table 13). The tetracycline-resistant-organisms varied from 
patient to patient and site to site. Table 14 shows the percentage of 
anaerobic organisms over the test period. The greatest reduction from 
Day 0 to Week 3 was seen in the sites receiving scaling as a treatment 
modality. The sites receiving placebo only showed an increase in the 
anaerobes, with the exception of patient JK, who showed 13.5% decrease 
in these organisms. Patient JC showed a slightly larger decrease (35% 
compared to 33.5%) in the percentage anaerobes when scaling was coupled 
with tetracycline therapy. All sites showed an increase in the percent-
age of anaerobes from Week 3 to Week 12 and there was a continued rise 
through the rest of the 24 week period. Table 15 shows the concomitant 
changes of the facultative organisms which inversely proportional to the 
anaerobes in Table 14. 
Table 16 shows the changes in percentages of the tetracycline-
resistant-organisms. The percentage increased significantly in three 
sites receiving tetracycline therapy but remained relatively constant 
in one site receiving tetracycline alone. When the means for all sites 
17 
are compared, the greatest increase in tetracycline resistant organisms 
occured in the sites treated by scaling and tetracycline therapy. There 
was a reduction in these organisms from Week 12 to Week 24 when comparing 
the means for all the sites. 
Figures 4 - 13 were developed for each patient to help demon-
strate the changes in the clinical and microbiological parameters over 
the 24 week period. The dramatic effect of scaling and/or tetracycline 
on these parameters can be seen from the baseline period to the third 
week. 
Figures 14 - 17 are a composite according to the treatment 
rendered. It can be seen that regardless of treatment, there is an 
improvement in the clinical parameters when there is a reduction in the 
anaerobic bacteria. 
CHAPTER V 
DISCUSSION 
From the results presented, it is apparent that at the treated 
diseased sites, the gingival index scores, the plaque index scores and 
the rpobing measurements were reduced from baseline values at the 3-, 
12- and 24-week examination periods as a result of the treatment con-
ditions, i.e. scaling, scaling plus tetracycline and tetracycline alone. 
When oral hygiene was the only treatment, as was the case with the sites 
treated by placebo only, there was a clinical improvement with regard 
to the gingival index and plaque index, but the pocket depths remained 
about the same or actually increased. The only time the pocket depths 
increased was when no treatment was rendered other than oral hygiene. 
Therefore, scaling and/or tetracycline therapy were probably responsible 
for the improvement in the clinical parameters. 
The main improvement in gingival index and plaque index scores 
occures in the first 12 weeks. No significant clinical improvement was 
noted after the 12 week period in the sites receiving sclaing plus a 
placebo. The sites receiving scaling plus tetracycline showed a con-
tinued clinical improvement past the 12 week period. The sites re-
ceiving tetracycline therapy alone showed no clinical improvement past 
the 12 week period. 
The changes in the relative percentages of the anaerobes and 
facultative is dramatic in those sites receiving scaling and/or tetra-
cycline therapy, with the percentage of anaerobes varying inversely to 
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the percentage of facultative organisms. The facultative organisms 
increased with scaling alone or in combination with tetracycline. 
These organisms also increased when tetracycline was administered but 
not as dramatically as when tetracycline was combined with scaling. 
An identical but reverse pattern was detected with respect to 
changes in the proportion of anaerobes, the proportions of which mark-
edly reduced by scaling and/or tetracycline therapy. However, there was 
a rebound effect after 3 weeks where the anaerobes gradually returned 
to theri baseline values. 
The results suggest that a microbial flora consistent with that 
observed at periodontally diseased sites can be shifted through treat-
ment to one more typical of the flora observed at healthy sites. 87 One 
would expect to see changes in the microflora with a broad spectrum 
antibiotic, but it is interesting to note that similar but less dramatic 
changes can be seen with conventional therapy. This effect on the micro-
flora lasted for nearly 12 weeks at which time the microflora approxi-
mated pretreatment levels. 
It would appear that the microbial shifts precede the clinical 
alterations and in fact may cause the clinical alterations. As the 
microflora returns to the baseline values at three months, the clinical 
parameters also return toward baseline values. Both scaling and tetra-
cycline, therefore, have a transient effect on the microflora and the 
clinical parameters described. 
Tetracycline-resistant organisms were found in all the subjects 
prior to therapy, and the proportions increased immediately after 
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tetracycline therapy. Sites treated with placebo only showed tetra-
cycline-resistant organisms and this would suggest a naturally occuring 
tetracycline-resistant population in the subgingival microflora. 
A variable which must be taken into account when reviewing the 
microbiological data is the effect of the sampling on the populations 
of the microflora. Mousques, et al. showed that sampling has a minor 
effect on the microbial content of the pockets. In that experiment, a 
periodontal curette was used. However, in sampling the periodontal 
pocket, various potential problems arise. The sample must be removed 
so that it is not contaminated with microorganisms in the vicinity of 
the sample site. Perhaps it is necessary to quantify the amount of 
plaque removed. 
Waerhaug in 1952, sterilized the tooth and gingival surfaces 
with glycerol and ethanol prior to sampling the contents of the gingival 
sulcus. He found that the sulcus was sterile when free of debris. Boyd90 
and Gavin 91 found that the glycerol-ethanol solution used by Waerhaug 
sterilized the gingival crevice and the solution penetrated into the 
crevice by capillary action. As a means to prevent contamination of 
the sample, Slots 92 exposed the sample site via a mucoperiosteal flap. 
The impracticality of this technique is obvious. Listgarten and Hellden87 
used a sterile curette to retrieve microbial samples and this became a 
popular technique but with the inherent problem that primarily adherent 
plaque was sampled and this may not be entirely representative. Finally, 
Slots, et a1. 81 used sterile paper points to sample pockets. The 
authors believed that this technique allowed for standardization of 
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the microbial flora from the entire pocket. The use of sterile paper 
points was used in this study for that reason. 
The use of tetracycline in periodontitis was discussed in 
Chapter 2. Chow, et a1. 93 showed that tetracycline inhibited 36% 
Bacteroides fragilis, 57% Bacteroides melaninogenicus, 60% Bacteroides 
corrodens, 68% Fusobacterium, 67% Peptostreptococcus, 67% Actinomyces 
at 6.25 ug/ml (blood concentration after therapeutic dose). It is 
because the tetracyclines are more effective against anaerobic bacteria 
that they have a real value in periodontal infections. 
A problem that arises with the tetracyclines is that resistant 
strains do develop and it was seen in this study that all the patient's 
studied had resistant strains. There are three principal means by 
which bacteria may be resistant to antimicrobial agents: 72 
1. Alternation of the target {ribobome) so that it is no 
longer susceptible to the action of the drug. 
2. Production of an enzyme which degrades the antibiotic. 
3. A change in the permeability of the bacterium to the agent. 
Acquired resistance to the tetracycline appears to be due to the second 
or third of the above mechanisms. 94 
Tetracycline resistance has been wide-spread among the Bacteroides 
fragilis group. It has been shown that its resistance is transferable to 
susceptible strains. In gram-negative facultative anaerobes, tetracycline 
resistance is generally an inducible property. 95 Therefore, care must 
be taken when using the tetracyclines. 
Therefore, does tetracycline have a value in treating periodon-
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tal disease considering the potential problems associated with this 
drug? This study showed that scaling alone, scaling in combination 
with tetracycline and tetracycline alone changed the microflora to that 
associated with health, but this was only a transient effect. Slots, 
et a1. 81 reported that two of the patients studied did not respond to 
conventional therapy, in that there was little or only moderate changes 
in the subgingival flora and in the clinical measurement. There was, 
however, marked changes when these patients were administered tetra-
cycline. This may be the real value of the antimicrobial agents. 
CHAPTER VI 
SUMMARY AND CONCLUSIONS 
Five patients were randomly assigned to two groups. One group 
received tetracycline and the other group received a placebo, both for 
a 14 day period. The tetracycline (Achromycin V) was administered 
orally in the dosage of 250mg four times a day. Within each group, the 
patient had one tooth scaled while the contralateral tooth was left 
untouched. After two baseline examinations of Gingival Index, Plaque 
Index, pocket depth and the microflora, examinations were made at week 
3, week 12 and week 24. 
As a result of this study, the following conclusions can be made: 
1. After one session of scaling and root planing alone, there 
was an improvement in the clinical parameters over a 12-week period. 
This trend reversed this time and continued through the 24th week. The 
percent microorganisms changed to that more compatible with health, but 
after the three week period, the composition reversed to baseline values. 
2. After one session of scaling and root planing plus tetracy-
cline administration, there was an improvement in the clinical parameters 
and this was sustained throughout the 24-week period. The percent micro-
organism change was similar to scaling and root planing alone, but the 
percent tetracycline-resistant organisms increased to a greater extent. 
3. Sites receiving tetracycline alone showed a deterioration of 
the clinical parameters from the 12- through 24th week. The percent 
change in microorganisms was not as great as the sites that also received 
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scaling and root planing. 
4. The site receiving placebo alone showed an improvement in 
the clinical parameters which may be due to the improvement in oral 
hygiene technique. The anaerobic microorganisms remained predominant 
and their percentage increased over the 24-week period. 
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Table 1. Organisms of the Human Gingival Crevice Region* 
Approximate 
Percentage of 
Cultivalbe 
Group Microbiota 
Gram-positive facultative cocci 28o8 
Gram-positive anaerobic cocci 7.4 
Gram-positive facultative rods 15.3 
Gram-positive anaerobic rods 20.2 
Gram-negative facultative cocci 0.4 
Gram-negative anaerobic cocci 10.7 
Gram-negative facultative rods 1.2 
Gram-negative anaerobic rods 16.1 
Spiral organisms 1 to 3 
*Adpated from Socransky, J. Dent. Res., 1970 
Genera and/or Species 
Commonly Found in 
this Site 
Staphylococci 
Enterococci 
S. mutans 
S. sanguis 
-rrs. mitis 11 
Peptostreptococcus 
Corynebacterium 
Lactobacillus 
Nocardia 
0. viscosus 
B. matruchotti 
A. bifi dus 
A. israelii 
A. naeslundii 
A. odontolyticus 
P. acnes 
I. buccal is 
Corynebacterium 
Neisseria 
V. alcalescens 
V. parvul a 
B. melaninogenicus 
B. oralis 
V. sputorum 
F. nucleatum 
S. sputigenum 
T. denticola 
T. ora 1 is 
T. macrodentium 
B. vi ncenti i 
Table 2. Distribution of Subgingival Organisms (X) in Health and Various Forms of Periodontal 
Disease* HEALTHY GINGIVITIS PERIODONTITIS 
Gram-~ositive organisms: Aged Healthy Gingivitis ANUG Incipient Advanced Rapid Abscess Juvenile 
Streptococcus X X X X X X X X 
Staphylococcus 
Actinomyces X X I X I X X X X X 
Rothia, Arachnia 
Peptococcus X X X X X X X X 
Peptostreptococcus X X X X X X X X 
Propionibacterium X X X X X X X X 
Other X X X X X X X X X 
Gram-negative organisms: 
Ve i 11 one 11 a X X X X X X X X 
Ei kene11 a X X X X X X 
Capnocytophaga X X X X X X X X 
Bacteroides 
Melaninogenicus X X X X X X X X 
Bacteroides X X X X X X X X X 
Fusobacteri urn X X X X X X X X X 
Leptotrichia X X 
Selenomonas X X X X X X 
Campylobacter X X X X X X X 
11 Vibrio-corroding 11 X X X X X X X X 
Unidentified X X X X X X X X X N 
0) 
Spirochetes X X X X X X X X X 
*Adapted from Grant, D.A.; Stern, I.B.; Everett, F.G. Periodontics, The C.V. Mosby Co., St. Louis, 1979. 
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Table 3. Side Effects and Toxicities of Tetracycline* 
Teeth Permanent discoloration, dysgenesis due to 
administration of tetracycline during last half 
of pregnancy or first 6 years of life. 
Bone Possible retardation of growth and development -
may be transient. 
Gastrointestinal 
Tract 
Liver 
Blood Urea 
Nitrogen 
Renal 
Vertigo 
Teratogenesis 
Skin 
Overgrowth with monilial microorganisms has been 
reported on a number of occasions in conjunction 
with tetracycline therapy. However, some articles 
question this statemento Alteration in absorption 
of vitamin K may occur leading to inadequate for-
mation of prothrombin-bleeding problems may follow. 
Lethal hepatic toxicity has been reported in con-
junction with use in pregnancy, shock and sepsis. 
Abnormal liver function tests have been reported. 
Elevation of blood urea nitrogen has been reported 
and appears to occur mainly in patients taking 
diuretics or presenting initially with a high blood 
urea nitrogen. Nausea, vomiting and the sequelae 
are associated with this rise. 
Azotemia. Also, renal disorders have been reported 
following administration during pregnancy. A Fanconi 
type syndrome has been associated with the use of 
outdated or degraded tetracycline. Therefore, they 
should be stored, until their expiration date, away 
from UV light sources, moisture and in a sealed 
containero Nephrogenic diabetes insipidus has been 
reported in conjunction with administration of 
demethylchlortetracycline. 
Reported with the use of minocycline. 
The literature suggests that these agents are poten-
tial teratogens, and have resulted in amlformed 
hands and limbs. Do not use in females in the 
childbearing age range who have missed one or more 
menstrual periods. 
Photosensitivity (especially with demethylchlor-
tetracycline), rash, oncholysis. 
*Adapted from Ciancio, Journal of Periodontal., 1976. 
Table 4. Description of Patients and Selected Sites 
Peri odonta 1 Probing 
Patient Age Race Sex Pocket Site Depth (mm) GI PI Therapy 
JC 25 c M 19 MB* 5 1.60 1.25 Scaling and root 
planing & TTC ** 
30 BF* 9 1.30 1.40 TTC only 
PL 25 c F 21 MB 8 2.00 1. 75 Scaling and root 
planing & placebo 
28 MB 7 2.00 1.88 Placebo only 
JK 26 c M 19 MB 7 1.83 1. 75 Scaling and root 
planing & placebo 
30 MB 6 2.66 1. 75 Placebo only 
BR 29 c F 19 MB 5 1.33 0.00 Scaling and root 
planing & TTC 
30 DB* 6 1.50 o.oo TTC only 
ss 31 c F 3 MB 9 2.00 2.00 Scaling and root 
planing & placebo 
14 t~B 9 2.00 2.00 Placebo only 
N 
*MB refers to mesial buccal; BF refers to buccal furcation; DB refers to distal buccal co 
**TTC refers to tetracycline 
Table 5. Criteria for the Gingival Index* 
Score Description 
0 Absence of inflammation 
l Mild inflammation; slight change in color and 
little change in texture. 
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2 Moderate inflammation; moderate galzing, redness, 
edema and hypertrophy. 
Bleeding on pressure. 
3 Severe inflammation; marked redness and hyper-
trophy. Tendency to spontaneous bleeding. 
Ulceration 
*Adapted from Loe and Silness, Acta Odontol. Scand., 1963. 
Table 6. Criteria for the Plaque Index** 
Score Description 
0 No plaque. 
l A film of plaque adhering to the free gingival 
margin and adjacent areas of the tooth. The plaque 
may be seen in site only after the application of 
disclosing solution or by using the probe on the 
tooth surface. 
2 Moderate accumulation of soft deposits within the 
gingival pocket or on the tooth and gingival margin 
which can be seen by the naked eye. 
3 Abundance of soft matter within the gingival pocket 
and/or the tooth and gingival margin. 
**Adapted from Silness and Loe, Acta Odontol. Scand., 1964. 
Table 7. Correlation of Mouth Scores to Degree 
of Inflammation and Plaque Accumulation* 
Mouth Scores (GI or PI) 
0.1 - 1.0 
1.1-2.0 
2.1 - 3.0 
Description 
Mild inflammation or plaque 
accumulation 
Moderate inflammation or plaque 
accumulation 
Severe inflammation or plaque 
accumulation 
*Adapted from Silness and Loe, Acta Odontol. Scand., 1964. 
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Table 8. Gingiva 1 Index Scores Over a 24 Week Period 
Subject & 
Treatment Oa.z:: 0* l~eek 3 Week 12 
PL 
l. P,s, 2.00 1.00 0.16 
2. PlSO 2.00 1.00 o.60 
JK 
1. P,s, 1.83 0.66 0.50 
2. PlSO 2.66 2.66 0.50 
ss 
l. Plsl 2.00 1.00 0.00 
2. PlSO 2.00 1.33 0.50 
JC 
l. T1 s1 1.60 1.00 0.60 
2. T1s0 1.30 1.00 0.20 
BR 
1. T1 s1 1.33 1.00 0.50 
2. T1s0 1.50 1.50 1.00 
x P1s1 1.94 0.88 0.22 
X PlSO 2.22 1.66 0.53 
x T1s1 1.46 1.00 0.55 
-x T1s0 1.40 1.25 0.60 
*mean of two scores taken at one week intervals 
X mean 
P1 Placebo 
s1 Scaled 
T1 Tetracycline 
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Week 24 
1.16 
1.60 
0.66 
0.66 
1.00 
1.00 
1.00 
1.00 
0.00 
1.16 
0.94 
1.08 
0.50 
1.30 
Table 9. Plaque Index Scores Over a 24 Week Period 
Subject & 
Treatment Da~ 0* ·Week 3 Week 12 
PL 
l. Plsl l. 75 1.00 0.00 
2. PlSO 1.87 1.00 0.00 
JK 
l. pl sl l. 75 1.00 0.00 
2. PlSO 1.75 1.16 0.00 
ss 
l. pl sl 2.00 1.00 0.25 
2. pl so 2.00 1.00 0.00 
JC 
1. T1s1 1.25 1.00 0.25 
2. T1s0 1.37 1.00 0.00 
BR 
l. T l s1 0.00 0.00 0.00 
2. T1s0 0.00 0.00 0.00 
X P1s1 1.83 1.00 0.08 
X P1s0 1.87 1.04 0.00 
x T1 s1 0.62 0.50 0.12 
x T1s0 0.68 0.50 0.00 
*mean of two scores taken at one week intervals 
X mean 
P1 Placebo 
s1 Scaled 
T1 Tetracycline 
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Week 24 
1.00 
1.00 
1.00 
1.00 
1.00 
0.50 
0.00 
0.25 
0.00 
0.25 
1.00 
0.83 
0.00 
0.12 
Table 10. Pocket Depths Over a 24 Week Period 
Subject & 
Treatment Da~ 0* Week 3 Week 12 
PL 
l. pl sl. 7.00 5.30 4.60 
2. PlSO 6.30 5.60 5.60 
JK 
l. pl sl 5.00 3.16 3.00 
2. PlSO 4.83 4.50 4.00 
ss 
l. pl sl 7.33 5.50 4.66 
2. PlSO 7.33 7.33 7.66 
JC 
l. T1 s1 4.60 3.50 3.60 
2. T1s0 6.50 5.00 5.20 
BR 
1 • T l s1 4.16 3.16 3.16 
2. T1s0 5.00 4.16 4.16 
x P1 s1 6.44 4.65 4.08 
X P1s0 6.15 5.81 5.75 
x T1s1 4.30 3.33 3.38 
x T1s0 5.75 4.58 4.68 
*mean of two scores taken at one week intervals 
X mean 
P1 Placebo 
s1 Scaled 
T1 Tetracycline 
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Week 24 
5.50 
6.80 
3.66 
4.50 
5.50 
7.83 
3.30 
5.20 
2.66 
4.33 
4.88 
6.37 
2.98 
4.76 
Table 11. Distribution of Subgingival Microflora In 5 Patients 
with Advanced Periodontal Disease. Baseline Values 
Obtained at One Week Intervals. (Percentage) 
Tetracycline 
Anaerobes Facultative Resistant 
Subject Site: #1 #2 #1 #2 #1 #2 
JC Sample 1 73 65 27 35 31 23 
Sample 2 65 66 35 34 27 47 
PL Sample 1 80 68 20 32 35 38 
Sample 2 73 63 27 37 30 49 
JK Sample 1 52 73 48 27 16 14 
Sample 2 60 64 40 36 26 20 
BR Sample 1 79 72 21 28 4 43 
Sample 2 68 69 32 31 5 50 
ss Sample 1 99 68 1 32 3 36 
Sample 2 99 58 1 42 2 46 
70.7 29.3 27.2 
X mean 
34 
Table 12. Distribution of the Subgingival Microflora 
In a Healthy Patient. (Percentage) 
Anaerobes 
Sample Site #1 #2 
#1 25 15 
#2 31 17 
X 22.0 
X mean 
Facultative 
#1 #2 
75 85 
69 83 
78.0 
Tetracycline 
Resistant 
#1 #2 
14 5 
5 7 
7.75 
35 
Table 13. Percentage of Anaerobic Bacteria 
Over a 24 Week Period 
Subject & 
Treatment Day 0* Week 3 Week 12 
PL 
1. P1s1 76.5 34.0 71.0 
2. PlSO 65.5 70.0 77.0 
JK 
1. P1 s1 56.0 30.0 56.0 
2. PlSO 68.5 55.0 58.0 
ss 
1. P1 s1 99.0 90.0 92.0 
2. PlSO 63.0 84.0 86.0 
JC 
1. T1 s1 69.0 34.0 73.0 
2. T1s0 65.5 32.0 78.0 
BR 
1 • T l s1 73.5 30.0 45.0 
2. T1s0 70.5 55.0 57.0 
X P1 s1 77.1 51.3 73.0 
X PlSO 65.6 69.6 73.6 
x T1s1 71.2 32.0 59.0 
x T1s0 68.0 43.5 67.5 
* mean of two scores taken at one week intervals 
X mean 
P1 Placebo 
s1 Sea 1 ed 
T1 Tetracycline 
36 
Heek 24 
76.0 
75.0 
84.0 
74.0 
96.0 
99.0 
78.0 
72.0 
62.0 
74.0 
85.3 
82.6 
70.0 
73.0 
Table 14. Percentage of Facultative Bacteria 
Over a 24 Heek Peri ad 
Subject & 
Treatment Da~ 0* l~eek 3 Heek 12 
PL 
l. pl sl 23.5 66.0 29.0 
2. pl so 34.5 30.0 23.0 
JK 
l. pl sl 44.0 70.0 44.0 
2. pl so 31.5 45.0 42.0 
ss 
l. pl sl 1.00 1 o. 0 8.00 
2. PlSO 37.0 16.0 14.0 
JC 
1 . T l s1 31.0 66.0 26.0 
2. T1s0 34.5 68.0 27.0 
BR 
l. T l s1 26.5 70.0 55.0 
2. T1s0 29.5 45.0 43.0 
x P1 s1 22.8 48.6 27.0 
X PlSO 34.3 30.3 26.3 
x T1 s1 28.7 68.0 40.5 
x T1s0 32.0 56.5 32.5 
*mean of two scores taken at one week intervals X mean 
P1 Placebo 
s1 Scaled 
T1 Tetracycline 
37 
Heek 24 
24.0 
25.0 
16.0 
26.0 
4.00 
1.00 
22.0 
28.0 
38.0 
26.0 
14.6 
17.3 
30.0 
32.0 
Table 15. Percentage of Tetracycline - Resistant Bacteria 
Over a 24 Week Period 
Subject & 
Treatment Oat 0* Week 3 Week 12 
PL 
l. pl sl 32.5 22.0 27.0 
2. PlSO 43.5 46.0 49.0 
JK 
1. pl sl 21.0 5.00 21.0 
2. PlSO 17.0 49.0 16.0 
ss 
l. pl sl 2.50 15.0 8.00 
2. PlSO 41.0 35.0 28.0 
JC 
l. T1s1 29.0 64.0 59.0 
2. T1s0 35.0 64.0 47.0 
BR 
1 • T l s1 4.50 23.0 23.0 
2. T1s0 46.5 47.0 51.0 
x P1 s1 18.6 14.0 18.6 
X PlSO 33.8 43.3 31.0 
xT1s1 16.7 43.5 41.0 
x T1s0 40.7 55.5 49.0 
*mean of two scores taken at one week intervals 
X mean 
P1 Placebo 
s1 Scaled 
T1 Tetracycline 
Week 24 
18.0 
37.0 
16.0 
16.0 
10.0 
1.0 
25.0 
31.0 
31.0 
42.0 
14.6 
18.0 
28.0 
36.5 
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Figure 1. Patient PL. The effect of scaling and root planing plus a placebo on various clinical 
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Figure 2. Patient PL. The effect of a placebo only on various clinical 
subgingival microflora over a 24 week period. 
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Figure 6. Patient SS. The effect of a placebo only on various clinical parameters and on the 
subgingival microflora over a 24 week period. .p. .p. 
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Figure 7. Patient JC. The effect of scaling and root planing plus tetracycline on various 
clinical parameters and on the subgingival microflora over a 24 week period. ~ 
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Figure 8. Patient JC. The effect of tetracycline on various clinical parameters and on the 
subgingiv~l microflora over a 24 week period. 
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Figure 9. Patient BR. The effect of scaling and root planing plus tetracycline on various 
clinical parameters and on the subgingival microflora over a 24 week period. 
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Figure 10. Patient BR. The effect of tetracycline on various clinical 
subgingival microflora over a 24 week period. 
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Figure 11. Composite graph of patients PL, JK and SS. Comparison of the effect of scaling and 
root planing plus a placebo on various clinical parameters and on the subgingival 
microflora over a 24 week period. 
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Figure 12. Composite graph of patients PL, JK and SS. Comparison of the effect of a placebo on 
various clinical parameters and the subgingival microflora over a 24 week period. 
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various clinical parameters and on the subgingival microflora over a 24 week period. 
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